Evolus delivered Q2 revenue of $84.08M, beating consensus by a meaningful margin, with adjusted EBITDA swinging into positive territory. The 21% year-over-year revenue growth reflects sustained momentum in the U.S. toxin market and international expansion. Adjusted EBITDA profitability—a key metric for device and injectables makers—signals that the company's cost structure is now aligned with its revenue base.
Business & M&A
Evolus Q2 Revenue Surges 21%, Adjusted EBITDA Swings Positive
Jeuveau revenue accelerates past forecasts; adjusted EBITDA turns positive as profitability gains traction.
1-YEAR MOVE
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Adjusted EBITDA swings positive; revenue beats consensus on 21% YoY growth.
The profitability inflection matters for practice economics. A stable, cash-generative Evolus is more likely to invest in market development, rebate programs, and supply chain resilience. For owners on Evolus Rewards or considering Jeuveau as a primary or secondary toxin, this quarter suggests the company has the financial runway to support competitive per-unit pricing and loyalty incentives through 2027.
Source: original report ↗
Frequently asked questions
Is Jeuveau a reliable toxin supplier for my medspa?
Yes. Evolus reported Q2 revenue of $84.08M with 21% year-over-year growth and positive adjusted EBITDA, signaling financial stability and the runway to support competitive pricing and loyalty programs through 2027. This profitability inflection indicates the company is positioned to invest in supply chain resilience and market development.
Will Jeuveau pricing stay competitive in 2024-2025?
Evolus's positive adjusted EBITDA and strong Q2 performance suggest the company has the financial capacity to maintain competitive per-unit pricing and rebate programs. Their improved cost structure alignment with revenue indicates sustainable economics for loyalty incentives through 2027.
What does Evolus adjusted EBITDA profitability mean for practices?
Positive adjusted EBITDA means Evolus is now cash-generative and can invest in market development, rebate programs, and supply chain resilience. For practices using Jeuveau, this translates to more stable supply, competitive pricing, and stronger incentive programs.
Should I switch to Jeuveau or add it as a secondary toxin?
Evolus's Q2 results—beating revenue forecasts with 21% growth and achieving profitability—demonstrate the company's financial health and commitment to the market. This makes Jeuveau a viable primary or secondary toxin option with confidence in long-term support and competitive economics.
How is Jeuveau performing compared to other toxins?
Jeuveau revenue accelerated past forecasts in Q2, driven by sustained momentum in the U.S. toxin market and international expansion. Evolus's profitability inflection and 21% YoY growth indicate strong market traction and competitive positioning.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.